Loading people...
Joseph Reth invests in deep technology and life sciences ventures, including biotechnology, advanced materials, AI for scientific discovery, and synthetic biology. His focus is on groundbreaking, self-sustaining innovations.
Joseph Reth works as the Co-Founder and CEO of Autopoiesis Sciences, an organization dedicated to investing in transformative deep tech and life sciences companies.
Joseph Reth is the San Francisco-based CEO of Autopoiesis Sciences, an artificial intelligence research laboratory developing autonomous scientific superintelligence alongside Eike Gerhardt and Larry Callahan. Before his current role, he dropped out of the computer science program at San Francisco State University to scale RethDigital, a digital agency he bootstrapped at age sixteen to a seven-figure annual recurring revenue before exiting. He subsequently served as the founding CEO of Lossless Research, an artificial intelligence laboratory where he developed the ECHO-1 agent that managed social media for over thirty brands and reached millions of global users. His machine learning work has been implemented in systems for the United States Department of Defense and prominently featured by the BBC. Reth currently focuses on advancing empirical consciousness studies, self-learning systems, and autonomous agents within the artificial intelligence sector.
Joseph Reth stands as the visionary Co-Founder and CEO of Autopoiesis Sciences, a pioneering organization dedicated to identifying and nurturing groundbreaking innovations within the deep technology and life sciences sectors. Under his strategic leadership, Autopoiesis Sciences has carved a niche for itself by investing in ventures that embody the principles of self-sustaining growth and transformative scientific impact. Reth's approach is rooted in a profound understanding of complex systems, aiming to support companies that are not only disruptive but also inherently capable of evolving and thriving independently.
As CEO, Joseph Reth guides Autopoiesis Sciences' overarching strategy, from deal sourcing and due diligence to portfolio management and strategic partnerships. His investment focus areas are broad yet specific, encompassing cutting-edge biotechnology, advanced materials, artificial intelligence applied to scientific discovery, synthetic biology, and other deep tech domains that promise to redefine industries and solve some of humanity's most pressing challenges. He is particularly interested in early-stage companies developing foundational technologies that can create new markets or significantly improve existing ones through scientific breakthroughs.
Joseph Reth's career background is marked by a consistent drive for innovation and entrepreneurship. While specific past ventures are not publicly detailed, his leadership at Autopoiesis Sciences reflects years of experience navigating the complex landscapes of scientific research, technological development, and venture capital. He possesses a unique ability to bridge the gap between complex scientific concepts and viable business models, making him a sought-after partner for founders pushing the boundaries of what's possible. His expertise lies in recognizing the long-term potential of nascent technologies and providing the strategic guidance necessary for them to achieve commercial success and societal impact.
Under Reth's stewardship, Autopoiesis Sciences seeks out companies that demonstrate strong scientific rigor, innovative intellectual property, and a clear path to market. He believes in fostering an ecosystem where scientific discovery can flourish into sustainable enterprises. While specific notable investments are proprietary to Autopoiesis Sciences, the firm's portfolio is designed to reflect Reth's commitment to fostering self-organizing and resilient technological advancements. Joseph Reth's influence extends beyond capital, offering mentorship and strategic insights that empower founders to build robust, future-proof companies. His dedication to advancing scientific frontiers through strategic investment positions him as a key figure in the deep tech and biotech investment landscape.
